4-((2-chloroethyl) (2-mesyloxyethyl)amino)benzoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 129762 |
| CHEMBL ID | 12644 |
| SCHEMBL ID | 1066049 |
| MeSH ID | M0244346 |
| Synonym |
|---|
| 4-cema-benzoic acid |
| CHEMBL12644 |
| 4-[2-chloroethyl(2-methylsulfonyloxyethyl)amino]benzoic acid |
| 122665-70-7 |
| 4-((2-chloroethyl) (2-mesyloxyethyl)amino)benzoic acid |
| 4-((2-chloroethyl)(2-((methylsulfonyl)oxy)ethyl)amino)benzoic acid |
| benzoic acid, 4-((2-chloroethyl)(2-((methylsulfonyl)oxy)ethyl)amino)- |
| SCHEMBL1066049 |
| 4-[(2-chloroethyl)[2-[(methylsulfonyl)oxy]ethyl]amino]benzoic acid |
| DTXSID70153673 |
| 4-[(2-chloroethyl)(2-mesyloxyethyl)amino] benzoic acid |
| PD069136 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The resulting conjugate was used in combination with a prodrug of a benzoic acid mustard alkylating agent to treat human colon tumor xenografts in a two-step targeting strategy, antibody-directed enzyme prodrug therapy (ADEPT)." | ( Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug. Bagshawe, KD; Blakey, DC; Boyle, FT; Burke, PJ; East, S; Melton, RG; Springer, CJ; Valcaccia, BE; Wright, AF, ) | 0.13 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID23577 | Kinetic parameter (half-life) was evaluated | 1998 | Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26 | Self-immolative nitrogen mustard prodrugs for suicide gene therapy. |
| AID102183 | Inhibitory concentration was evaluated against colorectal tumar cell line LoVo | 1996 | Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5 | New mustard prodrugs for antibody-directed enzyme prodrug therapy: alternatives to the amide link. |
| AID24282 | Chemical half-life in percholate at 37 degree was determined | 1994 | Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15 | Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. |
| AID101151 | Cytotoxicity was evaluated against LS174T-stCPG2(Q)3-expressing cell clone | 1998 | Journal of medicinal chemistry, Dec-17, Volume: 41, Issue:26 | Self-immolative nitrogen mustard prodrugs for suicide gene therapy. |
| AID237174 | Chemical half life period as substrates of CPG2 was determined | 2005 | Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16 | Novel fluorinated prodrugs for activation by carboxypeptidase G2 showing good in vivo antitumor activity in gene-directed enzyme prodrug therapy. |
| AID101132 | Compound was evaluated for its cytotoxicity without carboxypeptidase G2 in the colorectal cell line LS174T for 1 hour | 1994 | Journal of medicinal chemistry, Jul-22, Volume: 37, Issue:15 | Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.14) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||